← Leaderboards
Caitlin Eileen Martin
Virginia Commonwealth University
$3,787,017
Attributed
$4,596,824
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,596,824 · 5
By mechanism
R01$1,989,401 · 2
UG3$1,153,945 · 1
K23$1,026,540 · 1
R34$426,938 · 1
Top collaborators
- James M Bjork1 shared
- Frederick Gerard Moeller1 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Frederick Gerard Moeller$65,095,599
- Albert Arias$6,848,452
- William B Rizzo$4,693,472
- Zhongming Zhao$10,491,216
- Courtney Elizabeth Smith$107,138
Others in their field
Other Emerging Leaders on “Addiction”
- Eve Jelstrom · The Emmes Company, Llc$35,258,152
- Jeffrey Reich · Sparian Biosciences, Inc.$17,713,936
- Emmanuel Aja Oga · Research Triangle Institute$17,220,162
- Suparna Goswami · Univ Of North Carolina Chapel Hill$16,919,767
- Mark Brian Reed · San Diego State University$13,246,314
- Nikej Shah · Nirsum Laboratories, Inc.$12,506,430
Research focus
AddictionOpioid Use DisorderBuprenorphinePharmaceutical PreparationsTreatment OutcomeCause Of DeathRecoveryOverdoseReportingImpulsivityOverdose RiskNational Institute Of Drug AbuseBehavior TherapyClinical TrialsIndividualized MedicineSubstance UseStressMedication For Opioid Use DisorderImpairmentInnovationOpioidBiopsychosocialPhenotypeEmotional
Grant awards (11)
Novel 5-HT2A/mGluR5 Antagonist for Opioid Use Disorder$1,153,945
UG3 · FY2025 · DA
Neurofunctional phenotyping to investigate the role of the orexin system at the intersection of opioid use disorder and insomnia$762,021
R01 · FY2025 · DA · contact PI
A mechanistic study of the role of the orexin system and insomnia within a buprenorphine opioid use disorder treatment sample$465,669
R01 · FY2025 · DA · contact PI
Adaptation and Refinement of a Clinically Applicable Phenotypic Battery to Individualize Opioid Use Disorder Treatment for Women Through the Postpartum Period$205,308
K23 · FY2025 · DA · contact PI
Development and testing of cognitive behavioral therapy for insomnia adapted for patients in opioid use disorder treatment$194,063
R34 · FY2025 · DA · contact PI
Neurofunctional phenotyping to investigate the role of the orexin system at the intersection of opioid use disorder and insomnia$761,711
R01 · FY2024 · DA · contact PI
Health equity informed delivery of cognitive behavioral therapy for insomnia adapted for individuals with opioid use disorder$232,875
R34 · FY2024 · DA · contact PI
Adaptation and Refinement of a Clinically Applicable Phenotypic Battery to Individualize Opioid Use Disorder Treatment for Women Through the Postpartum Period$205,308
K23 · FY2024 · DA · contact PI
Adaptation and Refinement of a Clinically Applicable Phenotypic Battery to Individualize Opioid Use Disorder Treatment for Women Through the Postpartum Period$205,308
K23 · FY2023 · DA · contact PI
Adaptation and Refinement of a Clinically Applicable Phenotypic Battery to Individualize Opioid Use Disorder Treatment for Women Through the Postpartum Period$205,308
K23 · FY2022 · DA · contact PI
Adaptation and Refinement of a Clinically Applicable Phenotypic Battery to Individualize Opioid Use Disorder Treatment for Women Through the Postpartum Period$205,308
K23 · FY2021 · DA · contact PI